Find Nintedanib Esylate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

API REF. PRICE (USD/KG)

MARKET PLACE

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as:
Molecular Formula
C31H33N5O4
Molecular Weight
539.6  g/mol
InChI Key
XZXHXSATPCNXJR-ZIADKAODSA-N

Nintedanib Esylate
1 2D Structure

Nintedanib Esylate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
methyl (3Z)-3-[[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]anilino]-phenylmethylidene]-2-oxo-1H-indole-6-carboxylate
2.1.2 InChI
InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-
2.1.3 InChI Key
XZXHXSATPCNXJR-ZIADKAODSA-N
2.1.4 Canonical SMILES
CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)NC(=C3C4=C(C=C(C=C4)C(=O)OC)NC3=O)C5=CC=CC=C5
2.1.5 Isomeric SMILES
CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N/C(=C\3/C4=C(C=C(C=C4)C(=O)OC)NC3=O)/C5=CC=CC=C5
2.2 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 539.6 g/mol
Molecular Formula C31H33N5O4
XLogP33.3
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count7
Rotatable Bond Count8
Exact Mass539.25325455 g/mol
Monoisotopic Mass539.25325455 g/mol
Topological Polar Surface Area94.2 A^2
Heavy Atom Count40
Formal Charge0
Complexity947
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count1
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameOfev
Drug LabelOFEV capsules contain nintedanib, a kinase inhibitor [see Mechanism of Action (12.1)]. Nintedanib is presented as the ethanesulfonate salt (esylate), with the chemical name 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[(4-methyl-1-piperazin...
Active IngredientNintedanib
Dosage FormCapsule
RouteOral
Strength150mg; 100mg
Market StatusPrescription
CompanyBoehringer Ingelheim

2 of 2  
Drug NameOfev
Drug LabelOFEV capsules contain nintedanib, a kinase inhibitor [see Mechanism of Action (12.1)]. Nintedanib is presented as the ethanesulfonate salt (esylate), with the chemical name 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[(4-methyl-1-piperazin...
Active IngredientNintedanib
Dosage FormCapsule
RouteOral
Strength150mg; 100mg
Market StatusPrescription
CompanyBoehringer Ingelheim

API SUPPLIERS

read-more
read-more

01

Fermion Oy

Finland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Cosmoprof India
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothWith Fermion, start the journey of your innovative API.

Flag Finland
Digital Content Digital Content
USDMF arrow-down Click Us! arrow-down
CEP/COS JDMF EU-WC NDC KDMF arrow-down VMF ASMF arrow-down AUDIT
fermion

02

Metrochem API Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Cosmoprof India
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Metrochem

03

Midas Pharma

Germany

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Cosmoprof India
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMidas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

Flag Germany
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Midas Pharma

04

Veranova

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Cosmoprof India
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothVeranova: A CDMO that manages complexity with confidence.

Flag U.S.A
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Veranova

05

Inabata France S.A.S

France

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Cosmoprof India
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothIKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

Flag France
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Inabata Company Banner

06

Hubei Gedian Humanwell Pharmaceuti...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Cosmoprof India
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHubei Gedian Humanwell focuses on R&D, production, & sales of fertility regulation drugs & steroidal APIs.

Flag China
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
Hubei Gedian Humanwell Pharmaceutical

07

Jinan Tantu Chemicals

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothJinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Jinan Tantu Chemicals

08

Omgene Life Sciences Pvt. Ltd

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Cosmoprof India
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothOmgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Omgene Company Banner

09

Sichuan Kelun Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Cosmoprof India
Not Confirmed
arrow

Sichuan Kelun Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Cosmoprof India
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

10

Glenmark Life Sciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Cosmoprof India
Not Confirmed
arrow

Glenmark Life Sciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Cosmoprof India
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WCarrow-down NDC KDMF VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-more

01

Fermion Oy

Finland
arrow
CPHI Middle east
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothWith Fermion, start the journey of your innovative API.

Flag Finland
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2019-03-26

Pay. Date : 2018-12-20

DMF Number : 33361

Submission : 2019-01-02

Status : Active

Type : II

fermion

02

Veranova Lp

U.S.A
arrow
CPHI Middle east
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothVeranova: A CDMO that manages complexity with confidence.

Flag U.S.A
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2018-04-27

Pay. Date : 2018-03-30

DMF Number : 32511

Submission : 2018-03-29

Status : Active

Type : II

Veranova

03

CPHI Middle east
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHubei Gedian Humanwell focuses on R&D, production, & sales of fertility regulation drugs & steroidal APIs.

Flag China
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2018-12-03

Pay. Date : 2018-09-20

DMF Number : 33152

Submission : 2018-09-28

Status : Active

Type : II

Hubei Gedian Humanwell Pharmaceutical

04

Cipla Ltd

India

USDMF

arrow
CPHI Middle east
Not Confirmed

04

Cipla Ltd

India
arrow
CPHI Middle east
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2018-06-05

Pay. Date : 2018-03-19

DMF Number : 32504

Submission : 2018-03-29

Status : Active

Type : II

blank

05

CPHI Middle east
Not Confirmed

06

CPHI Middle east
Not Confirmed

07

CPHI Middle east
Not Confirmed

07

CPHI Middle east
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2019-11-05

Pay. Date : 2019-10-10

DMF Number : 32152

Submission : 2017-12-28

Status : Active

Type : II

blank

08

CPHI Middle east
Not Confirmed

08

CPHI Middle east
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2020-01-24

Pay. Date : 2019-12-02

DMF Number : 34332

Submission : 2019-12-20

Status : Active

Type : II

blank

09

CPHI Middle east
Not Confirmed

09

CPHI Middle east
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2018-09-05

Pay. Date : 2018-03-07

DMF Number : 31526

Submission : 2017-03-27

Status : Active

Type : II

blank

10

Olon Spa

Italy

USDMF

arrow
CPHI Middle east
Not Confirmed
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

Fermion Oy

Finland
arrow
Cosmoprof India
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothWith Fermion, start the journey of your innovative API.

Flag Finland
Digital Content Digital Content

Nintedanib Esylate

About the Company : Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services covering both APIs & F...

Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services covering both APIs & Formulations. API portfolio consists of >30 generic APIs & >10 NCEs & 2 mfg. sites as well as R&D facilities are all located in Finland. Fermion has invested & expanded capabilities in the production of HPAPIs. Drug product CMO services include hormonal & non-hormonal semi-solids, cytotoxic oral solids & packaging. We have 3 mfg. sites & one packaging center for drug products at Orion.
fermion

02

arrow
Cosmoprof India
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

Nintedanib Esylate

About the Company :

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product ...

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product groups and has been approved by ISO 9001-2015, USFDA, WHO GMP, Cofepris & Japanese authorities. Metrochem’s in-depth industry knowledge, & hi-tech & advanced infrastructure, helps it provide quality products to its customers. Note: None of the products will be supplied to the countries where this could conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
Metrochem

03

Midas Pharma

Germany
arrow
Cosmoprof India
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMidas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

Flag Germany
Digital Content Digital Content

Nintedanib Esylate

About the Company : Midas Pharma is a pharmaceutical company that excels in providing extensive expertise while fostering connections between companies, individuals, and knowledge. The core competence...

Midas Pharma is a pharmaceutical company that excels in providing extensive expertise while fostering connections between companies, individuals, and knowledge. The core competence of Midas Pharma lies in project management related to pharmaceutical supply chains. The company is actively involved in sourcing, supplying, and developing Active Pharmaceutical Ingredients (API) and Finished Dosage Forms (FDF) manufactured by its contract manufacturing partners. For each project or product, Midas Pharma selects the most suitable match from its network of manufacturing partners.
Midas Pharma

04

Veranova

U.S.A
arrow
Cosmoprof India
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothVeranova: A CDMO that manages complexity with confidence.

Flag U.S.A
Digital Content Digital Content

Nintedanib Esylate

About the Company : Veranova is a global leader in the development and manufacturing of specialist and complex APIs for pharma and biotech customers. We have over 50 years of experience navigating the...

Veranova is a global leader in the development and manufacturing of specialist and complex APIs for pharma and biotech customers. We have over 50 years of experience navigating the challenges of the global healthcare industry, and nurturing long-standing, trusted customer relationships. Operating within two divisions, Generics and Originators, we deliver a differentiated service offering to pharma and biotech customers for every stage in the drug development lifecycle. Macfarlan Smith Limited is trading as Veranova in the United Kingdom.
Veranova

05

arrow
Cosmoprof India
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothIKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

Flag France
Digital Content Digital Content

Nintedanib Esylate

About the Company : Established in 1990, Inabata France, a part of the Inabata Group, used to export chemical and pharmaceutical products to Japan. In 2006, it acquired Pharmasynthèse. Today, Inabata...

Established in 1990, Inabata France, a part of the Inabata Group, used to export chemical and pharmaceutical products to Japan. In 2006, it acquired Pharmasynthèse. Today, Inabata-Pharmasynthèse offers a wide range of services, including sourcing, manufacturing, and the development of raw materials for the pharmaceutical and cosmetic industries. It supplies these ingredients to Europe, Japan, and other countries. With expertise in fine chemical production, Inabata-Pharmasynthèse conducts manufacturing operations, ranging from pilot to commercial quantities, at its GMP-certified facility at St. Pierre-Les-Elbeuf in France.
Inabata Company Banner

06

arrow
Cosmoprof India
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHubei Gedian Humanwell focuses on R&D, production, & sales of fertility regulation drugs & steroidal APIs.

Flag China
Digital Content Digital Content

Nintedanib Esylate

About the Company : Hubei Gedian Humanwell Pharmaceutical Co., Ltd. is a modern high-tech pharmaceutical company with a focus on the research and development, production, and sales of fertility regula...

Hubei Gedian Humanwell Pharmaceutical Co., Ltd. is a modern high-tech pharmaceutical company with a focus on the research and development, production, and sales of fertility regulation drugs and steroidal APIs. It operates as a wholly-owned subsidiary of Humanwell Healthcare Group (Stock Code: 600079), one of the leading pharmaceutical conglomerates in China. The company operates two APIs manufacturing sites, one formulation factory, and one excipients factory, showcasing its commitment to integrating the reproductive health industry chain from raw materials and active pharmaceutical ingredients (APIs) to finished dosage forms.
Hubei Gedian Humanwell Pharmaceutical

07

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothJinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

Flag China
Digital Content Digital Content

Nintedanib Esylate

About the Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include c...

Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include customized R&D as well as the production of small molecule pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs) for both international and domestic pharmaceutical firms. Our capabilities span from laboratory-scale kilograms to commercial ton-scale production. Additionally, we are committed to independent research and development, as well as the production and sales of high-end pharmaceutical intermediates and API products.
Jinan Tantu Chemicals

08

arrow
Cosmoprof India
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothOmgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

Flag India
Digital Content Digital Content

Nintedanib

About the Company : Omgene Life Sciences Private Limited is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically...

Omgene Life Sciences Private Limited is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically integrated company, we focus on developing high-quality formulations based on in-house-produced actives. With GMP-certified facilities and partnerships with contract manufacturers, we excel in formulation development for injectables, lyophilized injectables, complex generics, and oral peptide delivery systems, ensuring affordable, top-quality medicines.
Omgene Company Banner

09

Cipla

India
Cosmoprof India
Not Confirmed
arrow

Cipla

India
arrow
Cosmoprof India
Not Confirmed

nintedanib

About the Company : Cipla is a global pharmaceutical company whose goal is ensuring no patient shall be denied access to high quality & affordable medicine and support. Mission: Cipla’s mission i...

Cipla is a global pharmaceutical company whose goal is ensuring no patient shall be denied access to high quality & affordable medicine and support. Mission: Cipla’s mission is to be a leading global healthcare company which uses technology and innovation to meet everyday needs of all patients. Since inception in 1935, caring has been at the core of everything we do at Cipla. For patients, caring is a promise that we will do whatever it takes to ensure they have continued access to the highest quality medicines at affordable prices; whether a disease affects millions or just a few hundreds.
blank

10

Cosmoprof India
Not Confirmed
arrow
arrow
Cosmoprof India
Not Confirmed

Nintedanib Esylate

About the Company : Formosa Laboratories Inc. founded in Taiwan since 1995 started with API business and has been serving customers worldwide. As an established API manufacturer receiving GMP inspecti...

Formosa Laboratories Inc. founded in Taiwan since 1995 started with API business and has been serving customers worldwide. As an established API manufacturer receiving GMP inspections from regulatory authorities around the world, Formosa now provides CDMO service extending from APIs and ADCs (Antibody Drug Conjugates) to cytotoxic and non-cytotoxic injectables of aseptic liquid filling and lyophilization. Formosa Laboratories is able to offer full-service GMP manufacturing for drug substance, ADCs and drug product with its API and injectable facilities that accommodates small molecules, biologics and ADCs etc.
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"NINTEDANIB ESYLATE","year":"2021","qtr":"Q1","strtotime":1610389800,"product":"NINTEDANIB ESYLATE (GROUP:B) (TAX INVOIC E NO:1905205230 DT:05.01.2021","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"OSAKA","customer":"TOWA PHARMACEUTICAL","customerCountry":"JAPAN","quantity":"0.10","actualQuantity":"100","unit":"GMS","unitRateFc":"16.6","totalValueFC":"1678.7","currency":"USD","unitRateINR":1227.73,"date":"12-Jan-2021","totalValueINR":"122773","totalValueInUsd":"1678.7","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"7868504","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q1","strtotime":1611081000,"product":"NINTEDANIB (BASE) (BATCH NO: ZV0020120)","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"NEW YORK","customer":"DISPERSOL TECHNOLOGIES LLC","customerCountry":"UNITED STATES","quantity":"0.40","actualQuantity":"0.4","unit":"KGS","unitRateFc":"14567.3","totalValueFC":"5899.7","currency":"USD","unitRateINR":1078710,"date":"20-Jan-2021","totalValueINR":"431484","totalValueInUsd":"5899.7","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"8025769","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"NINTEDANIB ESYLATE","year":"2021","qtr":"Q1","strtotime":1614623400,"product":"NINTEDANIB ESYLATE (GROUP:B) (TAX INVOIC E NO:1905205283 DT:22.02.2021","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"OSAKA","customer":"TOWA PHARMACEUTICAL","customerCountry":"JAPAN","quantity":"2.90","actualQuantity":"2.9","unit":"KGS","unitRateFc":"14923.1","totalValueFC":"42830.2","currency":"USD","unitRateINR":1075206.8965517241,"date":"02-Mar-2021","totalValueINR":"3118100","totalValueInUsd":"42830.2","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"9039929","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"NINTEDANIB ESYLATE","year":"2021","qtr":"Q1","strtotime":1616005800,"product":"NINTEDANIB ESYLATE (GROUP:B) (TAX INVOIC E NO:1905205310 DT:15.03.2021","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"SEOUL","customer":"DAEWOONG PHARMACEUTICAL","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"9801.7","totalValueFC":"4850.3","currency":"USD","unitRateINR":706212,"date":"18-Mar-2021","totalValueINR":"353106","totalValueInUsd":"4850.3","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"9457612","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1625077800,"product":"NINTEDANIB ESYLATE (TAX INVOICE NO:19052 15104 DT:28-06-2021","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"CHICAGO O\\'HARE INT\\'L","customer":"PATHEON","customerCountry":"UNITED STATES","quantity":"0.10","actualQuantity":"100","unit":"GMS","unitRateFc":"8.6","totalValueFC":"833.1","currency":"USD","unitRateINR":620.89999999999998,"date":"01-Jul-2021","totalValueINR":"62090","totalValueInUsd":"833.1","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"2828972","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1625164200,"product":"NINTEDANIB ESYLATE (TAX INVOICE NO:19052 15105 DT:28-06-2021","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"STOCKHOLM","customer":"DISRUPTIVE MATERIALS AB","customerCountry":"SWEDEN","quantity":"0.02","actualQuantity":"20","unit":"GMS","unitRateFc":"5.3","totalValueFC":"101.6","currency":"USD","unitRateINR":378.55000000000001,"date":"02-Jul-2021","totalValueINR":"7571","totalValueInUsd":"101.6","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"2858398","productDescription":"API","marketType":"REGULATED MARKET","country":"SWEDEN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1625596200,"product":"NINTEDANIB ESYLATE (TAX INVOICE NO:19052 15037 DT:08-05-2021)(GROUP:A","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"STOCKHOLM","customer":"XSPRAY PHARMA","customerCountry":"SWEDEN","quantity":"0.15","actualQuantity":"150","unit":"GMS","unitRateFc":"19.7","totalValueFC":"2860.7","currency":"USD","unitRateINR":1421.3133333333333,"date":"07-Jul-2021","totalValueINR":"213197","totalValueInUsd":"2860.7","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"2972909","productDescription":"API","marketType":"REGULATED MARKET","country":"SWEDEN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1632940200,"product":"NINTEDANIB ESYLATE (TAX INVOICE NO:19052","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"OSAKA","customer":"TOWA PHARMACEUTICAL","customerCountry":"JAPAN","quantity":"16.60","actualQuantity":"16.6","unit":"KGS","unitRateFc":"15000","totalValueFC":"245349","currency":"USD","unitRateINR":1087168.6746987952,"date":"30-Sep-2021","totalValueINR":"18047000","totalValueInUsd":"245349","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"4977066","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1635791400,"product":"NINTEDANIB ESYLATE","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"PARIS","customer":"PHDS","customerCountry":"FRANCE","quantity":"0.40","actualQuantity":"400","unit":"GMS","unitRateFc":"4.8","totalValueFC":"1889.3","currency":"USD","unitRateINR":351.73750000000001,"date":"02-Nov-2021","totalValueINR":"140695","totalValueInUsd":"1889.3","indian_port":"Dahez-SEZ","hs_no":"29349990","bill_no":"4014431","productDescription":"API","marketType":"REGULATED MARKET","country":"FRANCE","selfForZScoreResived":"Pharma Grade","supplierPort":"Dahez-SEZ","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1640802600,"product":"NINTEDANIB ESYLATE (TAX INVOICE NO:19052","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"SEOUL","customer":"DAEWOONG PHARMACEUTICAL","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"10000","totalValueFC":"4905.5","currency":"USD","unitRateINR":740000,"date":"30-Dec-2021","totalValueINR":"370000","totalValueInUsd":"4905.5","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"7147403","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1643740200,"product":"NINTEDANIB ESYLATE (TAX INVOICE NO:19052","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"GAVA AIRFARM LOGISTICS ","customerCountry":"UNITED ARAB EMIRATES","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"5940","totalValueFC":"11620","currency":"USD","unitRateINR":435500,"date":"02-Feb-2022","totalValueINR":"871000","totalValueInUsd":"11620","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"7937263","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1653417000,"product":"NINTEDANIB ESYLATE BATCH NO : FDP220089","address":"CIPLA HOUSE, PENINSULA BUSINESS,PA RK,GANPATRAO KADAM MARG,LOWER","city":"PAREL MUMBAI MAHARASHTRA,MAHARASHTR","supplier":"CIPLA","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"PHARMAPIA CO. LTD.","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"8000","totalValueFC":"659.9","currency":"USD","unitRateINR":510000,"date":"25-May-2022","totalValueINR":"51000","totalValueInUsd":"659.9","indian_port":"BANGALORE AIR","hs_no":"29280090","bill_no":"1640442","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"CIPLA HOUSE, PENINSULA BUSINESS,PA RK,GANPATRAO KADAM MARG,LOWER, PAREL MUMBAI MAHARASHTRA,MAHARASHTR","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1666895400,"product":"NINTEDANIB ESYLATE, BATCH:FDP220198,MFG","address":"CIPLA HOUSE, PENINSULA BUSINESS,PA RK,GANPATRAO KADAM MARG,LOWER","city":"PAREL MUMBAI MAHARASHTRA,MAHARASHTR","supplier":"CIPLA","supplierCountry":"INDIA","foreign_port":"OSAKA - KANSAI INT\\'L","customer":"TOWA PHARMACEUTICAL","customerCountry":"JAPAN","quantity":"41.50","actualQuantity":"41.5","unit":"KGS","unitRateFc":"6500","totalValueFC":"269189","currency":"USD","unitRateINR":533734.93975903618,"date":"28-Oct-2022","totalValueINR":"22150000","totalValueInUsd":"269189","indian_port":"BANGALORE AIR","hs_no":"29280090","bill_no":"5095042","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"CIPLA HOUSE, PENINSULA BUSINESS,PA RK,GANPATRAO KADAM MARG,LOWER, PAREL MUMBAI MAHARASHTRA,MAHARASHTR","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1692729000,"product":"NINTEDANIB ESYLATE(NET QTY:80 GMS)","address":"MSN HOUSE PLOT NO. C-24INDUSTRI AL ESTATE SANATH NAGAR","city":"Hyderabad","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"NA","customer":"TO THE ORDER OF","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.08","actualQuantity":"80","unit":"GMS","unitRateFc":"9.1","totalValueFC":"724.3","currency":"USD","unitRateINR":749.99999249999996,"date":"23-Aug-2023","totalValueINR":"59999.9994","totalValueInUsd":"724.3","indian_port":"HYDERABAD ICD","hs_no":"29337990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"SOUTH KOREA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD ICD","supplierAddress":"MSN HOUSE PLOT NO. C-24INDUSTRI AL ESTATE SANATH NAGAR, Hyderabad","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1696444200,"product":"NINTEDANIB ESYLATE","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"PHILADELPHIA METROP","customer":"TO THE ORDER OF","customerCountry":"UNITED STATES","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"5000","totalValueFC":"4842","currency":"USD","unitRateINR":403000,"date":"05-Oct-2023","totalValueINR":"403000","totalValueInUsd":"4842","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"4410880","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1699554600,"product":"NINTEDANIB ESYLATE","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"TO THE ORDER OF","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"7500","totalValueFC":"3650.7","currency":"USD","unitRateINR":608000,"date":"10-Nov-2023","totalValueINR":"304000","totalValueInUsd":"3650.7","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"5283476","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1700850600,"product":"NINTEDANIB ESYLATE","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"TO THE ORDER OF","customerCountry":"KOREA, REPUBLIC OF","quantity":"19.00","actualQuantity":"19000","unit":"GMS","unitRateFc":"10","totalValueFC":"187388.4","currency":"USD","unitRateINR":821.26315789473688,"date":"25-Nov-2023","totalValueINR":"15604000","totalValueInUsd":"187388.4","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"5582396","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1703615400,"product":"NINTEDANIB ESYLATE","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"KUKJEON PHARMACEUTICAL","customerCountry":"KOREA, REPUBLIC OF","quantity":"18.50","actualQuantity":"18.5","unit":"KGS","unitRateFc":"7500","totalValueFC":"137440.7","currency":"USD","unitRateINR":618432.43243243243,"date":"27-Dec-2023","totalValueINR":"11441000","totalValueInUsd":"137440.7","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"6331506","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1706812200,"product":"NINTEDANIB ESYLATE","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"KUKJEON PHARMACEUTICAL","customerCountry":"KOREA, REPUBLIC OF","quantity":"18.50","actualQuantity":"18.5","unit":"KGS","unitRateFc":"7500","totalValueFC":"137339","currency":"USD","unitRateINR":615974.86486486485,"date":"02-Feb-2024","totalValueINR":"11395535","totalValueInUsd":"137339","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"7220852","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1709145000,"product":"NINTEDANIB ESYLATE","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"KUKJEON PHARMACEUTICAL CO.LTD.","customerCountry":"KOREA, REPUBLIC OF","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"7500","totalValueFC":"74221.9","currency":"USD","unitRateINR":615846.80000000005,"date":"29-Feb-2024","totalValueINR":"6158468","totalValueInUsd":"74221.9","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"7930672","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1709490600,"product":"HSN CODE : 29349990 SAP CODE : 2020774 HARMLESS PHARMACEUTICAL BULK DRUG NINTEDANIB ESYLATE","address":"ACME PLAZA, ANDHERI KURLA ROAD,","city":"MUMBAI, MAHARASHTRA.","supplier":"SUN PHARMACEUTICAL INDUSTRIES LIMITED","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"M\/S","customerCountry":"TAIWAN","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"9000","totalValueFC":"17715.9","currency":"USD","unitRateINR":735528,"date":"04-Mar-2024","totalValueINR":"1471056","totalValueInUsd":"17715.9","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"8042317","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"ACME PLAZA, ANDHERI KURLA ROAD,, MUMBAI, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1721068200,"product":"NINTEDANIB ESYLATE","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"KUKJEON PHARMACEUTICAL CO.,LTD,","customerCountry":"REPUBLIC OF KOREA","quantity":"40.00","actualQuantity":"40","unit":"KGS","unitRateFc":"6500","totalValueFC":"256336.8","currency":"USD","unitRateINR":535686.59999999998,"date":"16-Jul-2024","totalValueINR":"21427464","totalValueInUsd":"256336.8","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"2463847","productDescription":"API","marketType":"REGULATED MARKET","country":"REPUBLIC OF KOREA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1637001000,"product":"NINTEDANIB ESYLATE (FINE)(BATCH NO.F275F-21001)","address":"B\/2 MAHALAXMI CHAMBERS 22 BHULABHAI DESAI ROAD Contact No:","city":"MUMBAI","supplier":"FORMOSA LABORATORIES","supplierCountry":"TAIWAN","foreign_port":"NA","customer":"GLENMARK PHARMACEUTICALS","customerCountry":"INDIA","quantity":"6.00","actualQuantity":"6","unit":"KGS","unitRateFc":"6510","totalValueFC":"39625.8","currency":"USD","unitRateINR":"491830.5","date":"16-Nov-2021","totalValueINR":"2950983","totalValueInUsd":"39625.8","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"6277954","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"B\/2 MAHALAXMI CHAMBERS 22 BHULABHAI DESAI ROAD Contact No:"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1719340200,"product":"NINTEDANIB API (BATCH NO.82232178) (RE-IMPORT)","address":"20TH KM, HOSUR ROAD,","city":"BANGALORE","supplier":"EIRGEN PHARMA","supplierCountry":"INDIA","foreign_port":"DUBLIN","customer":"BIOCON","customerCountry":"INDIA","quantity":"40.64","actualQuantity":"40.635","unit":"KGS","unitRateFc":"2700","totalValueFC":"112591.5","currency":"USD","unitRateINR":"231304.9","date":"26-Jun-2024","totalValueINR":"9399075.21","totalValueInUsd":"112591.5","indian_port":"Bangalore Air","hs_no":"29349990","bill_no":"4199410","productDescription":"Re-Import","marketType":"REGULATED MARKET","country":"INDIA","selfForZScoreResived":"Pharma Grade","supplierPort":"DUBLIN","supplierAddress":"WESTSIDE BUSINESS PARK OLD KILMEADEN ROAD, WATERFORD Dublin, , IRELANDSDNF IRELAND","customerAddress":"20TH KM, HOSUR ROAD,"}]
12-Jan-2021
16-Jul-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

The inhaled therapeutic candidate MNKD-201 (nintedanib) is being evaluated in early-stage clinical trial studies for treating patients suffering from pulmonary fibrotic diseases.


Lead Product(s): Nintedanib Esylate

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: MNKD-201

Study Phase: Phase IProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 04, 2024

blank

01

Mannkind

U.S.A
arrow
Antibody Engineering
Not Confirmed

Mannkind

U.S.A
arrow
Antibody Engineering
Not Confirmed

Details : The inhaled therapeutic candidate MNKD-201 (nintedanib) is being evaluated in early-stage clinical trial studies for treating patients suffering from pulmonary fibrotic diseases.

Brand Name : MNKD-201

Molecule Type : Small molecule

Upfront Cash : Not Applicable

November 04, 2024

blank

Details:

AP02 (nintedanib) is a multiple tyrosine kinase inhibitor, being evaluated in early-stage clinical trial studies for treating patients suffering from pulmonary fibrotic diseases.


Lead Product(s): Nintedanib Esylate

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: AP02

Study Phase: Phase IProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 12, 2024

blank

02

Antibody Engineering
Not Confirmed
Antibody Engineering
Not Confirmed

Details : AP02 (nintedanib) is a multiple tyrosine kinase inhibitor, being evaluated in early-stage clinical trial studies for treating patients suffering from pulmonary fibrotic diseases.

Brand Name : AP02

Molecule Type : Small molecule

Upfront Cash : Not Applicable

August 12, 2024

blank

Details:

The inhaled therapeutic candidate MNKD-201 (nintedanib) is being evaluated in early-stage clinical trial studies for treating patients suffering from pulmonary fibrotic diseases.


Lead Product(s): Nintedanib Esylate

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: MNKD-201

Study Phase: IND EnablingProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 30, 2024

blank

03

Mannkind

U.S.A
arrow
Antibody Engineering
Not Confirmed

Mannkind

U.S.A
arrow
Antibody Engineering
Not Confirmed

Details : The inhaled therapeutic candidate MNKD-201 (nintedanib) is being evaluated in early-stage clinical trial studies for treating patients suffering from pulmonary fibrotic diseases.

Brand Name : MNKD-201

Molecule Type : Small molecule

Upfront Cash : Not Applicable

April 30, 2024

blank

Details:

OFEV (nintedanib) is an investigational drug in development for fibrosing interstitial lung disease. It inhibits profibrotic mediators including platelet-derived growth factor, TGF-β as well as VEGF, reducing fibroblast activity.


Lead Product(s): Nintedanib Esylate

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Ofev

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 25, 2023

blank

04

Antibody Engineering
Not Confirmed
Antibody Engineering
Not Confirmed

Details : OFEV (nintedanib) is an investigational drug in development for fibrosing interstitial lung disease. It inhibits profibrotic mediators including platelet-derived growth factor, TGF-β as well as VEGF, reducing fibroblast activity.

Brand Name : Ofev

Molecule Type : Small molecule

Upfront Cash : Not Applicable

July 25, 2023

blank

Details:

AP02 (nintedanib) is an investigational drug in development for pulmonary fibrosis. It inhibits profibrotic mediators including platelet-derived growth factor, fibroblast growth factor and transforming growth factor (TGF)-β as well as VEGF, reducing fibroblast activity.


Lead Product(s): Nintedanib Esylate

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: AP02

Study Phase: Phase IProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 30, 2023

blank

05

Antibody Engineering
Not Confirmed
Antibody Engineering
Not Confirmed

Details : AP02 (nintedanib) is an investigational drug in development for pulmonary fibrosis. It inhibits profibrotic mediators including platelet-derived growth factor, fibroblast growth factor and transforming growth factor (TGF)-β as well as VEGF, reducing fib...

Brand Name : AP02

Molecule Type : Small molecule

Upfront Cash : Not Applicable

March 30, 2023

blank

Details:

The InPedILD results showed that the weight-based dosing regimen of Ofev (nintedanib) in children and adolescents with fibrosing ILD resulted in comparable exposure to that observed in adult patients with fibrosing ILD.


Lead Product(s): Nintedanib Esylate

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Ofev

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 05, 2022

blank

06

Antibody Engineering
Not Confirmed
Antibody Engineering
Not Confirmed

Details : The InPedILD results showed that the weight-based dosing regimen of Ofev (nintedanib) in children and adolescents with fibrosing ILD resulted in comparable exposure to that observed in adult patients with fibrosing ILD.

Brand Name : Ofev

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 05, 2022

blank

Details:

No significant drug-drug interaction (DDI) seen with BLD-0409 (cudetaxestat) in combination with either pirfenidone or nintedanib, two approved therapies for idiopathic pulmonary fibrosis (IPF).


Lead Product(s): Cudetaxestat,Nintedanib Esylate

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: BLD-0409

Study Phase: Phase IProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 16, 2022

blank

07

Antibody Engineering
Not Confirmed
Antibody Engineering
Not Confirmed

Details : No significant drug-drug interaction (DDI) seen with BLD-0409 (cudetaxestat) in combination with either pirfenidone or nintedanib, two approved therapies for idiopathic pulmonary fibrosis (IPF).

Brand Name : BLD-0409

Molecule Type : Small molecule

Upfront Cash : Not Applicable

May 16, 2022

blank

Details:

In an analysis of SENSCIS-ON, the safety profile of Ofev in participants who continued therapy for an additional 52 weeks was consistent with that observed during the SENSCIS trial.


Lead Product(s): Nintedanib Esylate

Therapeutic Area: Immunology Brand Name: Ofev

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 14, 2021

blank

08

Antibody Engineering
Not Confirmed
Antibody Engineering
Not Confirmed

Details : In an analysis of SENSCIS-ON, the safety profile of Ofev in participants who continued therapy for an additional 52 weeks was consistent with that observed during the SENSCIS trial.

Brand Name : Ofev

Molecule Type : Small molecule

Upfront Cash : Not Applicable

May 14, 2021

blank

Details:

OFEV® is the first treatment available in Canada for chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as PF-ILD), which affects patients across more than 200 rare lung disorders.


Lead Product(s): Nintedanib Esylate

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: OFEV

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 04, 2021

blank

09

Antibody Engineering
Not Confirmed
Antibody Engineering
Not Confirmed

Details : OFEV® is the first treatment available in Canada for chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as PF-ILD), which affects patients across more than 200 rare lung disorders.

Brand Name : OFEV

Molecule Type : Small molecule

Upfront Cash : Not Applicable

March 04, 2021

blank

Details:

New study will assess the potential impact of nintedanib in patients developing pulmonary fibrosis following acute lung injury from COVID-19 infection. Research collaboration will lead to insights about pulmonary fibrosis in the growing COVID-19 patient population.


Lead Product(s): Nintedanib Esylate

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Ofev

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Icahn School of Medicine

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration November 19, 2020

blank

10

Antibody Engineering
Not Confirmed
Antibody Engineering
Not Confirmed

Details : New study will assess the potential impact of nintedanib in patients developing pulmonary fibrosis following acute lung injury from COVID-19 infection. Research collaboration will lead to insights about pulmonary fibrosis in the growing COVID-19 patient ...

Brand Name : Ofev

Molecule Type : Small molecule

Upfront Cash : Undisclosed

November 19, 2020

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATES SUPPLIERS

read-more
read-more

01

Fermion Oy

Finland
Antibody Engineering
Not Confirmed
arrow
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothWith Fermion, start the journey of your innovative API.

CAS Number : 1168152-07-5

End Use API : Nintedanib Esylate

About The Company : Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services co...

fermion

02

Fermion Oy

Finland
Antibody Engineering
Not Confirmed
arrow
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothWith Fermion, start the journey of your innovative API.

CAS Number : 262368-30-9

End Use API : Nintedanib Esylate

About The Company : Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services co...

fermion

03

Almelo

India
Antibody Engineering
Not Confirmed
arrow

Almelo

India
Antibody Engineering
Not Confirmed
arrow

CAS Number : CAS-1160293-25-3

End Use API : Nintedanib Esylate

About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...

blank

04

Almelo

India
Antibody Engineering
Not Confirmed
arrow

Almelo

India
Antibody Engineering
Not Confirmed
arrow

CAS Number : CAS-14192-26-8

End Use API : Nintedanib Esylate

About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...

blank

05

Almelo

India
Antibody Engineering
Not Confirmed
arrow

Almelo

India
Antibody Engineering
Not Confirmed
arrow

CAS Number : CAS-1160293-27-5

End Use API : Nintedanib Esylate

About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...

blank

06

Almelo

India
Antibody Engineering
Not Confirmed
arrow

Almelo

India
Antibody Engineering
Not Confirmed
arrow

CAS Number : CAS-1160293-24-2

End Use API : Nintedanib Esylate

About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...

blank

07

Almelo

India
Antibody Engineering
Not Confirmed
arrow

Almelo

India
Antibody Engineering
Not Confirmed
arrow

CAS Number : CAS-1160293-22-0

End Use API : Nintedanib Esylate

About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...

blank

08

Aventus Labs

India
Antibody Engineering
Not Confirmed
arrow

Aventus Labs

India
Antibody Engineering
Not Confirmed
arrow

CAS Number : 14192-26-8

End Use API : Nintedanib Esylate

About The Company : Aventus Labs is a forward-thinking pharmaceutical company committed to developing and delivering high-quality, effective healthcare solutions. With a focus on r...

blank

09

Aventus Labs

India
Antibody Engineering
Not Confirmed
arrow

Aventus Labs

India
Antibody Engineering
Not Confirmed
arrow

CAS Number : 2653-16-9

End Use API : Nintedanib Esylate

About The Company : Aventus Labs is a forward-thinking pharmaceutical company committed to developing and delivering high-quality, effective healthcare solutions. With a focus on r...

blank

10

Antibody Engineering
Not Confirmed
arrow
Antibody Engineering
Not Confirmed
arrow

CAS Number : 14192-26-8

End Use API : Nintedanib Esylate

About The Company : Fujian South Pharmaceutical Co., Ltd. (Southern Pharmaceutical) was established in September 2001 and is located in Mingxi County, Fujian Province. After 16 ye...

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

APIs

read-more
read-more
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
Antibody Engineering
Not Confirmed
arrow
Antibody Engineering
Not Confirmed

NINTEDANIB ESYLATE

US Patent Number : 9907756

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 205832

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-06-07

blank

02

arrow
Antibody Engineering
Not Confirmed
arrow
Antibody Engineering
Not Confirmed

NINTEDANIB ESYLATE

US Patent Number : 10154990*PED

Drug Substance Claim :

Drug Product Claim :

Application Number : 205832

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2026-07-08

blank

03

arrow
Antibody Engineering
Not Confirmed
arrow
Antibody Engineering
Not Confirmed

NINTEDANIB ESYLATE

US Patent Number : 10154990

Drug Substance Claim :

Drug Product Claim :

Application Number : 205832

Patent Use Code : U-2620

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2026-01-08

blank

04

arrow
Antibody Engineering
Not Confirmed
arrow
Antibody Engineering
Not Confirmed

NINTEDANIB ESYLATE

US Patent Number : 10154990*PED

Drug Substance Claim :

Drug Product Claim :

Application Number : 205832

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2026-07-08

blank

05

arrow
Antibody Engineering
Not Confirmed
arrow
Antibody Engineering
Not Confirmed

NINTEDANIB ESYLATE

US Patent Number : 10154990

Drug Substance Claim :

Drug Product Claim :

Application Number : 205832

Patent Use Code : U-2620

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2026-01-08

blank

06

arrow
Antibody Engineering
Not Confirmed
arrow
Antibody Engineering
Not Confirmed

NINTEDANIB ESYLATE

US Patent Number : 10105323*PED

Drug Substance Claim :

Drug Product Claim :

Application Number : 205832

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-12-04

blank

07

arrow
Antibody Engineering
Not Confirmed
arrow
Antibody Engineering
Not Confirmed

NINTEDANIB ESYLATE

US Patent Number : 10105323*PED

Drug Substance Claim :

Drug Product Claim :

Application Number : 205832

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-12-04

blank

08

arrow
Antibody Engineering
Not Confirmed
arrow
Antibody Engineering
Not Confirmed

NINTEDANIB ESYLATE

US Patent Number : 9907756*PED

Drug Substance Claim :

Drug Product Claim :

Application Number : 205832

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-12-07

blank

09

arrow
Antibody Engineering
Not Confirmed
arrow
Antibody Engineering
Not Confirmed

NINTEDANIB ESYLATE

US Patent Number : 9907756*PED

Drug Substance Claim :

Drug Product Claim :

Application Number : 205832

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-12-07

blank

10

arrow
Antibody Engineering
Not Confirmed
arrow
Antibody Engineering
Not Confirmed

NINTEDANIB ESYLATE

US Patent Number : 6762180*PED

Drug Substance Claim :

Drug Product Claim :

Application Number : 205832

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2026-04-01

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty